» Articles » PMID: 10433230

The Role of Gonadotropin-releasing Hormone in Murine Preimplantation Embryonic Development

Overview
Journal Endocrinology
Specialty Endocrinology
Date 1999 Aug 5
PMID 10433230
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have established the presence of an extrahypothalamic GnRH in a variety of tissues. GnRH receptor is known to be present in the placenta, which produces and secretes the decapeptide from the very early stages of placentation. We hypothesized that GnRH may play a role in the preimplantation development of embryos. To examine this hypothesis, we assessed GnRH and GnRH receptor messenger RNA (mRNA; RT-PCR) and protein expression (Immunohistochemistry) in preimplantation murine embryos at various developmental stages. Furthermore, preimplantation murine embryos were cultured with GnRH agonist and antagonist in vitro to assess the influence of GnRH analogs on embryo development. GnRH is expressed in the developing mouse embryo from morula to hatching blastocyst stages at the mRNA and protein levels. GnRH receptor mRNA is also present in the developing embryos studied. Preimplantation embryonic development was significantly enhanced by incubation with increasing concentrations of GnRH agonist and is significantly decreased by GnRH antagonist compared with that in the control group. Moreover, GnRH antagonist (5 and 10 microM) was able to completely block embryo development. The deleterious effect of GnRH antagonist on embryo development was reversed by increasing concentrations of the agonist, as determined by the number of embryos reaching the blastocyst stage.

Citing Articles

Ganirelix and the prevention of premature luteinizing hormone surges.

Mannaerts B F S Rep. 2023; 4(2 Suppl):56-61.

PMID: 37223764 PMC: 10201301. DOI: 10.1016/j.xfre.2023.02.009.


Additional single dose GnRH agonist during luteal phase support may improve live birth rate in GnRHa-HRT frozen-thawed embryo transfer cycle: a retrospective cohort study.

Chang W, Lin P, Li C, Chern C, Chen Y, Lin L BMC Pregnancy Childbirth. 2023; 23(1):174.

PMID: 36918869 PMC: 10012576. DOI: 10.1186/s12884-023-05491-y.


GnRH agonist and hCG (dual trigger) versus hCG trigger for follicular maturation: a systematic review and meta-analysis of randomized trials.

Hu K, Wang S, Ye X, Zhang D, Hunt S Reprod Biol Endocrinol. 2021; 19(1):78.

PMID: 34059045 PMC: 8167939. DOI: 10.1186/s12958-021-00766-5.


Intraindividual Embryo Morphokinetics Are Not Affected by a Switch of the Ovarian Stimulation Protocol Between GnRH Agonist vs. Antagonist Regimens in Consecutive Cycles.

Dietrich J, Freis A, Beedgen F, von Horn K, Holschbach V, Liebscher J Front Endocrinol (Lausanne). 2020; 11:246.

PMID: 32411093 PMC: 7198727. DOI: 10.3389/fendo.2020.00246.


Administration effects of single-dose GnRH agonist for luteal support in females undertaking IVF/ICSI cycles: A meta-analysis of randomized controlled trials.

Song M, Liu C, Hu R, Wang F, Huo Z Exp Ther Med. 2019; 19(1):786-796.

PMID: 31885714 PMC: 6913329. DOI: 10.3892/etm.2019.8251.